DIAGNOS Welcomes Mr. François Côté to its Board of Directors
June 18 2019 - 9:33AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF) a leader in early detection of critical health issues
through the use of its FL
AIRE platform based on
Artificial Intelligence (AI), is pleased to announce the
appointment of Mr. François Côté to its board of directors.
Mr. Côté is currently Vice Chair of the TELUS
Fund, an independent organization established to promote health and
individual wellness. He is also Lead Director of EXFO Inc., Lead
Director of Alithya and Lead Director of Purkinje Inc. He is
Executive Chairman of the Board of HZB Pharma Canada. He also
serves on the Board of Aspire Food Group and on the Advisor
Committee of Groupe Morneau.
Formerly President and CEO at Emergis Inc., a
publicly-traded company, Mr. Côté was appointed President, TELUS
Health Solutions, following TELUS’ acquisition of Emergis in
January 2008. Mr. Côté held the position of President of TELUS
Québec before being named Executive Vice President of TELUS and
Vice-Chair of TELUS Québec, TELUS Health and TELUS Ventures in 2012
and in 2014-15 as Chair of TELUS Ventures.
“We are delighted to have François joining the
Board. Going forward, I am convinced that DIAGNOS will greatly
benefit from his vast experience and business relationships in
healthcare and finance,” said Mr. Georges Hebert, Chairman of the
board of directors of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024